Nektar Therapeutics (NKTR) EBT (2016 - 2025)
Historic EBT for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$35.0 million.
- Nektar Therapeutics' EBT rose 547.13% to -$35.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$113.8 million, marking a year-over-year increase of 3238.07%. This contributed to the annual value of -$119.2 million for FY2024, which is 5684.18% up from last year.
- According to the latest figures from Q3 2025, Nektar Therapeutics' EBT is -$35.0 million, which was up 547.13% from -$39.4 million recorded in Q2 2025.
- Nektar Therapeutics' EBT's 5-year high stood at $7.0 million during Q4 2024, with a 5-year trough of -$159.0 million in Q2 2022.
- Over the past 5 years, Nektar Therapeutics' median EBT value was -$52.3 million (recorded in 2024), while the average stood at -$74.3 million.
- Per our database at Business Quant, Nektar Therapeutics' EBT crashed by 5673.46% in 2021 and then surged by 11656.45% in 2024.
- Nektar Therapeutics' EBT (Quarter) stood at -$146.8 million in 2021, then soared by 56.77% to -$63.5 million in 2022, then surged by 33.65% to -$42.1 million in 2023, then skyrocketed by 116.56% to $7.0 million in 2024, then plummeted by 602.09% to -$35.0 million in 2025.
- Its EBT was -$35.0 million in Q3 2025, compared to -$39.4 million in Q2 2025 and -$46.4 million in Q1 2025.